Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII

Aging Cell

Volumn 14, Issue 5, 2015, Pages 754-763

  Wei, Yan ^a   Han, Chanshuai ^a   Wang, Yujing ^a,b   Wu, Beibei ^a,b   Su, Tao ^a   Liu, Ying ^a,c   He, Rongqiao ^a,d  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

Hyperphosphorylation; Ribosylation; Tau protein

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; GLUCOSE; PHOSPHATASE; PHOSPHOTRANSFERASE; RIBOSE; TAU PROTEIN; CK59 COMPOUND; GUANIDINE DERIVATIVE; KINETIN; MAPT PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL LYSATE; CELL VIABILITY; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GLYCATION; HIPPOCAMPUS; IN VITRO STUDY; MALE; MEMORY; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPATIAL LEARNING; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PHOSPHORYLATION; TUMOR CELL CULTURE;

ALZHEIMER DISEASE; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; INJECTIONS, INTRAPERITONEAL; KINETIN; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; RIBOSE; TAU PROTEINS; TUMOR CELLS, CULTURED;

EID: 84940895607     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12355     Document Type: Article

References (59)

1. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B (1987) Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. 74, 209-225.
2. Anonymous (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853.
3. Baudier J, Cole RD (1987) Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids. J. Biol. Chem. 262, 17577-17583.
4. Bierman EL, Baker EM, Plough IC, Hall WH (1959) Metabolism of d-ribose in diabetes mellitus. Diabetes 8, 455-458.
5. 2+/calmodulin-dependent protein kinase. Neuron 1, 63-72.
6. Cai Y, Liu J, Shi Y, Liang L, Mou S (2005) Determination of several sugars in serum by high-performance anion-exchange chromatography with pulsed amperometric detection. J. Chromatogr. A 1085, 98-103.
7. Chen L, Wei Y, Wang X, He R (2009) D-Ribosylated Tau forms globular aggregates with high cytotoxicity. Cell. Mol. Life Sci. 66, 2559-2571.
8. Chen L, Wei Y, Wang X, He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5, e9052.
9. Cloos PA, Christgau S (2002) Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biol. 21, 39-52.
10. 2+/calmodulin-dependent protein kinase II by basal autophosphorylation. J. Biol. Chem. 268, 7163-7170.
11. Day JF, Thorpe SR, Baynes JW (1979) Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum. J. Biol. Chem. 254, 595-597.
12. Dukic-Stefanovic S, Schinzel R, Riederer P, Munch G (2001) AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2, 19-34.
13. Gross M, Kormann B, Zollner N (1991) Ribose administration during exercise: effects on substrates and products of energy metabolism in healthy subjects and a patient with myoadenylate deaminase deficiency. Klin. Wochenschr. 69, 151-155.
14. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089.
15. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9, 294-299.
16. Han C, Lu Y, Wei Y, Liu Y, He R (2011) D-ribose induces cellular protein glycation and impairs mouse spatial cognition. PLoS One 6, e24623.
17. Han C, Lu Y, Wei Y, Wu B, Liu Y, He R (2014) D-ribosylation induces cognitive impairment through RAGE-dependent astrocytic inflammation. Cell Death Dis. 5, e1117.
18. Hanson PI, Meyer T, Stryer L, Schulman H (1994) Dual role of calmodulin in autophosphorylation of multifunctional CaM kinase may underlie decoding of calcium signals. Neuron 12, 943-956.
19. 2+/calmodulin-dependent protein kinase analyzed by site-directed mutagenesis. J. Biol. Chem. 267, 17216-17224.
20. Hashimoto N, Robinson FW, Shibata Y, Flanagan JE, Kono T (1987) Diversity in the effects of extracellular ATP and adenosine on the cellular processing and physiologic actions of insulin in rat adipocytes. J. Biol. Chem. 262, 15026-15032.
21. Hunter T (1987) A thousand and one protein kinases. Cell 50, 823-829.
22. 2+/calmodulin-independent activity of calmodulin-dependent protein kinase II by autophosphorylation. Autothiophosphorylation of the enzyme. J. Biol. Chem. 266, 11582-11588.
23. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 1739, 198-210.
24. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656-664.
25. Ishida A, Kitani T, Fujisawa H (1996) Evidence that autophosphorylation at Thr-286/Thr-287 is required for full activation of calmodulin-dependent protein kinase II. Biochim. Biophys. Acta 1311, 211-217.
26. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481.
27. Katoh T, Fujisawa H (1991) Autoactivation of calmodulin-dependent protein kinase II by autophosphorylation. J. Biol. Chem. 266, 3039-3044.
28. Keller PJ, Le Van Q, Kim SU, Bown DH, Chen HC, Kohnle A, Bacher A, Floss HG (1988) Biosynthesis of riboflavin: mechanism of formation of the ribitylamino linkage. Biochemistry 27, 1117-1120.
29. Konstantopoulos N, Marcuccio S, Kyi S, Stoichevska V, Castelli LA, Ward CW, Macaulay SL (2007) A purine analog kinase inhibitor, calcium/calmodulin-dependent protein kinase II inhibitor 59, reveals a role for calcium/calmodulin-dependent protein kinase II in insulin-stimulated glucose transport. Endocrinology 148, 374-385.
30. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268, 24374-24384.
31. Ksiezak-Reding H, Pyo HK, Feinstein B, Pasinetti GM (2003) Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim. Biophys. Acta 1639, 159-168.
32. Kwiatkowski AP, Shell DJ, King MM (1988) The role of autophosphorylation in activation of the type II calmodulin-dependent protein kinase. J. Biol. Chem. 263, 6484-6486.
33. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ (2012) AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol. Aging 33, 1400-1410.
34. Lindwall G, Cole RD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301-5305.
35. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 225, 54-62.
36. Lu Y, He RQ (2014) GRP75 of CHO cells responds to ribosylation. Prog. Biochem. Biophys. 41, 1191-1192.
37. Marks PA (1956) A newer pathway of carbohydrate metabolism; the pentose phosphate pathway. Diabetes 5, 276-283.
38. Mauser M, Hoffmeister HM, Nienaber C, Schaper W (1985) Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ. Res. 56, 220-230.
39. 2(+)-independent activity. Neuron 1, 593-604.
40. Murphy SP, Allen LH (2003) Nutritional importance of animal source foods. J. Nutr. 133, 3932S-3935S.
41. Nathan DM (1993) Long-term complications of diabetes mellitus. N. Engl. J. Med. 328, 1676-1685.
42. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J. Neurosci. 24, 2401-2411.
43. Qu MH, Fang CY, Zhang XR, Zhao CZ, Mao SM, Gao ZQ (2012) Type 2 diabetes and mild cognitive impairment. Prog. Biochem. Biophys. 39, 791-795.
44. Sadik G, Tanaka T, Kato K, Yamamori H, Nessa BN, Morihara T, Takeda M (2009) Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. J. Neurochem. 108, 33-43.
45. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888, 256-262.
46. Segal S, Foley J, Wyngaarden JB (1957) Hypoglycemic effect of D-ribose in man. Proc. Soc. Exp. Biol. Med. 95, 551-555.
47. Seuffer R (1977) A new method for the determination of sugars in cerebrospinal fluild (author's transl). J. Clin. Chem. Clin. Biochem. 15, 663-668.
48. Shecterle LM, Terry KR, St Cyr JA (2010) The patented uses of D-ribose in cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discovery 5, 138-142.
49. Sima AA (2010) Encephalopathies: the emerging diabetic complications. Acta Diabetol. 47, 279-293.
50. Su T, He R (2014) D-ribose, an overlooked player in type 2 diabetes mellitus? Sci. China Life Sci. 57, 361.
51. Su T, Xin L, He YG, Wei Y, Song YX, Li LW, Wang XM, He RQ (2013) The abnormally high level of uric D-ribose for type-2 diabetics. Prog. Biochem. Biophys. 40, 816-825.
52. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS (2002) Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25, 1055-1059.
53. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol. 85, 148-175.
54. Wei Y, Chen L, Chen J, Ge L, He RQ (2009) Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. BMC Cell Biol. 10, 10.
55. Wei Y, Han CS, Zhou J, Liu Y, Chen L, He RQ (2012a) d-ribose in glycation and protein aggregation. Biochim. Biophys. Acta 1820, 488-494.
56. Wei Y, Miao JY, Liu Y (2012b) Endogenous and exogenous factors in hyperphosphorylation of Tau in Alzheimer's disease. Prog. Biochem. Biophys. 39, 778-784.
57. Yang Y, Hu S, Zhang J, Zhang M, Gong C (2006) Alzheimer-like hyperphosphorylation of tau in brains of rats with obesity and type 2 diabetes. Prog. Biochem. Biophys. 33, 458-464.
58. Yang Y, Sun TT, Xu YP, Zhang JH, Zhang MX, Zhang XJ, Liu YJ, Yuan G (2010) rAAV-mediated VLDLR gene transfection reduces tau hyperphosphorylation in hippocampus of type 2 diabetic rats. Chin. J. Pathophysiol. 26, 245-250.
59. 2+/calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry. Neurosci. Lett. 353, 185-188.